GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates
December 04 2018 - 7:00AM
Business Wire
GlycoMimetics, Inc. (NASDAQ: GLYC) shared at the 60th American
Society of Hematology (ASH) Annual Meeting yesterday two posters
with preclinical data presentations: on GMI-1687, the company’s
highly potent E-selectin antagonist that is bioavailable via
subcutaneous administration, and GMI-1757, the company’s
dual-function E-selectin/galectin-3 antagonist.
“The new preclinical data presented at ASH underscore
GlycoMimetics’ commitment to pioneering advances in the field of
glycobiology and to rationally designing innovative drug candidates
that address areas of significant unmet medical need,” said John
Magnani, Ph.D., Senior Vice President and Chief Scientific Officer.
“The two compounds, debuted in posters, are currently in
preclinical testing. The GMI-1687 poster points to the potential
for a life-cycle extension for uproleselan, which is more
highly-potent and is subcutaneously bioavailable in animal models.
The poster on GMI-1757, a novel galectin-3/E-selectin antagonist,
suggests the compound may be able to play a role in the treatment
of a variety of cancers and fibrotic conditions.”
Details for the two poster presentations on GlycoMimetics’
wholly owned drug candidates follow:
- Publication Number:
4678TITLE: A Novel and Potent Inhibitor of E-Selectin,
GMI-1687, Attenuates Thrombus Formation and Augments
Chemotherapeutic Intervention of AML in Preclinical Models
Following Subcutaneous Administration
- Publication Number:
2211TITLE: A Novel Glycomimetic Compound (GMI-1757) with
Dual Functional Antagonism to E-Selectin and Galectin-3
Demonstrates Inhibition of Thrombus Formation in an
Inferior Vena Cava Model
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly owned drug candidate, uproleselan, an
E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial
as a potential treatment for AML and is currently being evaluated
in a company-sponsored Phase 3 trial in relapsed/refractory
AML. The U.S. Food and Drug Administration granted uproleselan
breakthrough therapy designation for the treatment of adult
AML) patients with relapsed/refractory disease.
GlycoMimetics has also completed a Phase 1 clinical trial with
a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin
antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the clinical development of the company’s drug candidates,
including the expected enrollment in and conduct of clinical
trials, the presentation of clinical data, and expiration of issued
patents. Actual results may differ materially from those in these
forward-looking statements. For a further description of the risks
associated with these statements, as well as other risks facing
GlycoMimetics, please see the risk factors described in the
company’s annual report on Form 10-K filed with the U.S. Securities
and Exchange Commission (SEC) on March 6, 2018, and other filings
GlycoMimetics makes with the SEC from time to time. Forward-looking
statements speak only as of the date of this release, and
GlycoMimetics undertakes no obligation to update or revise these
statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181204005097/en/
Investor Contact:Shari AnnesPhone: 650-888-0902Email:
sannes@annesassociates.com
Media Contact:Jamie Lacey-MoreiraPhone:
410-299-3310Email: jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024